In Depth 18 Sep 2024 Two targets, one solution: The rise of bispecific antibodies …biggest names in biotech and pharma are at the forefront of development in the field, including the likes of Amgen, Regeneron, Genentech, Janssen, and Pfizer. In fact, Regeneron made headlines… September 18, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Apr 2024 Silencing genes to cure diseases: an in-depth look at siRNA …era for gene-targeted therapies. The siRNA technology sector is gaining momentum as major biotech players have recently increased their focus on siRNA. Table of contents How does siRNA work? SiRNA… April 10, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? …to compare its efficacy to more advanced candidates such as capivasertib. Laekna’s afuresertib Initially developed by GSK, afuresrtib was then acquired by Novartis and later licensed out to Chinese biotech… July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2020 Coronavirus Pandemic Bites into European Cancer Research The UK funder Cancer Research UK and Swedish oncology biotech Alligator Bioscience have independently announced cuts to payroll and research costs due to the coronavirus disease pandemic. Cancer Research UK… April 10, 2020 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 22 Jan 2018 Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target …pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called Cellerix. The company became part… January 22, 2018 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2025 23andMe: the collapse of a genomics giant …ago. What was once a $6 billion company is now a penny stock. Layoffs and mass resignations plagued the genomics giant, and in the most recent turn of events, its… March 10, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2021 Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms …in 2015, and Oncorine, which Shanghai Sunway Biotech took to the Chinese market in 2005. Another oncolytic virus called Rigvir was approved in Latvia in 2004 but withdrawn in 2019…. January 26, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Sanofi drug reduces disease activity in relapsing MS …B. The most common adverse events (≥4%) in any frexalimab-treated group were COVID-19 and headache. About frexalimab Frexalimab (SAR441344) is a novel monoclonal antibody that is thought to block the… June 1, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nuance Pharma’s RSV vaccine cleared for trial in China …and is designed to run through the 2022/2023 RSV season with topline results expected mid-2023 if the pre-defined number of lower-respiratory tract disease events has occurred. Under this MVA-BN RSV… November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2018 Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient… April 25, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 HotSpot looks to boost cancer therapy pipeline with Excelra partnership U.S. biotech company HotSpot Therapeutics, Inc. is looking to increase its drug development and discovery efforts by partnering with Indian data and digital insights company Excelra. HotSpot discovers and develops… May 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Potential new cancer treatment target discovered by researchers in Sweden …HnRNPK prevents double-strand RNA forming between them and keeps them separate. Chandrasekhar Kanduri is professor of medical genetics at Sahlgrenska Academy, University of Gothenburg and is one of the research… August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email